Figure 1.

PCA treatment extends survival in the hSOD1^G93A mouse model of ALS. (A) Survival of hSOD1^G93A mice (untreated or treated with 50 or 100 mg/kg PCA) and wildtype mice (WT). Oral administration of either 50 or 100 mg/kg PCA beginning at disease onset (90 days of age) significantly extended median survival in hSOD1^G93A mice to 129 and 133 days, respectively, when compared to untreated hSOD1^G93A mice, which exhibited a median survival of 121 days. Curves are significantly different as determined by log-rank (Mantel–Cox) test (p = 0.0025; n = 15 mice per group). (B) Body weight of hSOD1^G93A mice (untreated or treated with 100 mg/kg PCA) and WT mice. Body weight was assessed twice per week and is expressed as the percent of peak body weight at each time point. Data are displayed as the mean ± SEM with n = 15 mice for each group.